Pharma cost not to be impacted by NPPA's curb on anti-infective drugs - (Business Line via NewsPoints Desk)

  • Following the move of the National Pharmaceutical Pricing Authority to cap the selling price of 43 drug formulations used to treat infections and gastro-intestinal disorders and few vaccines, commonly used antibiotic drugs such as ciprofloxacin, cloxacillin and rifampicin will now be reduced in price by as much as 50 percent, Business Line reported Friday.
  • However, the revenue loss for pharmaceutical companies from this move is not likely to be significant, said AIOCD AWACS.
  • The revenue impact for Ranbaxy and Cipla is expected to be around 55 crore Indian and 46 crore rupees, respectively, while Cadila Healthcare and Pfizer may see their sales drop by around 20 crore rupees and 13 crore rupees, respectively.

To read more NewsPoints articles, click here.